fat-4 Antibody

What is FAT4 and why is it important in research?

FAT4 (FAT Atypical Cadherin 4) is a member of the cadherin-associated protein family that functions as a tumor suppressor by inhibiting proliferation and metastasis. The canonical human protein has 4981 amino acid residues with a molecular mass of 542.7 kDa and localizes to the cell membrane. FAT4 plays crucial roles in nervous system development and cell adhesion, and has been implicated in cancer biology through its interaction with the Wnt/β-catenin pathway . The FAT4 gene has been associated with Van Maldergem syndrome, making it relevant for both developmental biology and oncology research . Its significant size and complex structure (containing thirty-four cadherin domains, six EGF-like domains, and two laminin G-like domains) make it an interesting but challenging protein to study .

What types of FAT4 antibodies are available for research purposes?

FAT4 antibodies are available in several formats, including:

• Polyclonal antibodies: Recognize multiple epitopes, useful for detection of denatured proteins

• Monoclonal antibodies: Recognize specific epitopes, like the mouse monoclonal IgG1 antibody (165E2K)

• Tagged/conjugated antibodies: Including fluorescent conjugates like DyLight 550 for immunofluorescence applications

• Application-specific antibodies: Optimized for Western Blot, Immunocytochemistry, Immunofluorescence, or Immunohistochemistry

Different antibodies recognize various regions of the FAT4 protein, such as those targeting the region between residues 4931 and 4981 at the C-terminus .

How should I select the appropriate FAT4 antibody for my specific application?

When selecting a FAT4 antibody, consider these factors:

• Application compatibility: Verify the antibody has been validated for your application (WB, ICC, IHC, etc.)

• Species reactivity: Ensure reactivity with your species of interest (human, mouse, rat, etc.)

• Epitope location: For studying specific domains or post-translational modifications, select antibodies that recognize relevant regions

• Antibody format: Consider whether native or denatured detection is required

• Conjugation requirements: For direct detection methods like flow cytometry or immunofluorescence, consider conjugated antibodies

Review published literature to identify antibody clones that have been successfully used in similar experimental contexts to yours.

What controls should I include when validating a new FAT4 antibody?

Proper validation requires these controls:

• Positive control: Tissues or cell lines known to express FAT4 (widely expressed across many tissue types)

• Negative control:

  • Tissues or cells where FAT4 is absent or knocked down

  • Isotype controls matching the FAT4 antibody's host species and isotype

  • Secondary antibody-only controls

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Comparison with multiple FAT4 antibodies recognizing different epitopes

  • Validation in FAT4 knockout or knockdown models

Documenting these validation steps is essential for publication-quality research.

What are the optimal conditions for using FAT4 antibodies in Western blotting?

For Western blot detection of FAT4:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • For membrane proteins like FAT4, include detergents (RIPA or NP-40)

• Gel selection:

  • Due to FAT4's large size (542.7 kDa), use low percentage (3-8%) gradient gels

  • Consider specialized high-molecular-weight protein separation systems

• Transfer conditions:

  • Extended transfer times (overnight at low voltage)

  • Use PVDF membranes rather than nitrocellulose for better binding of large proteins

• Blocking and antibody incubation:

  • Standard 5% non-fat milk or BSA in TBST

  • Primary antibody dilutions as recommended (typically 1:500-1:2000)

  • Extended primary antibody incubation (overnight at 4°C)

• Detection considerations:

  • Enhanced chemiluminescence with extended exposure times

  • Consider using fluorescent secondary antibodies for more quantitative results

How can I optimize immunofluorescence protocols when using FAT4 antibodies?

For optimal immunofluorescence results:

• Fixation method selection:

  • For membrane proteins like FAT4, 4% paraformaldehyde is often preferred

  • Avoid methanol fixation which can disrupt membrane protein epitopes

• Permeabilization:

  • Gentle permeabilization (0.1-0.2% Triton X-100 or 0.1% saponin)

  • For membrane proteins, digitonin may preserve membrane structure better

• Blocking and antibody conditions:

  • Extended blocking (1-2 hours) with serum matching secondary antibody species

  • Overnight primary antibody incubation at 4°C at optimized dilution

  • Consider directly conjugated antibodies (like DyLight 550-conjugated anti-FAT4) to reduce background

• Counterstaining suggestions:

  • Nuclear counterstain (DAPI or Hoechst)

  • Membrane markers to confirm colocalization (e.g., WGA, phalloidin)

  • Cilia markers for kidney studies as FAT4 localizes to primary cilia of kidney cells

• Imaging parameters:

  • Z-stack acquisition for complete cellular localization

  • Confocal microscopy for precise subcellular localization

Why might I observe inconsistent staining patterns with FAT4 antibodies?

Inconsistent FAT4 staining may result from:

• Biological variability:

  • FAT4 expression varies across tissues and has up to 3 different isoforms

  • Post-translational modifications, especially glycosylation, affect antibody recognition

  • Subcellular localization changes during development or disease progression

• Technical factors:

  • Fixation duration affecting epitope availability

  • Incomplete membrane permeabilization for intracellular epitopes

  • Antibody batch variability

  • Storage conditions affecting antibody quality

• Sample-specific issues:

  • FAT4 degradation during sample processing

  • Protein-protein interactions masking epitopes

  • Cell-type specific expression patterns

Systematic optimization of each experimental parameter and validation across multiple samples can help address inconsistency issues.

How can I address high background when using FAT4 antibodies in immunohistochemistry?

To reduce background in IHC:

• Antibody optimization:

  • Titrate antibody concentrations (typically start with 1:100-1:500 dilutions)

  • Test longer incubation times with more dilute antibody

• Blocking improvements:

  • Use dual blocking (protein block followed by serum block)

  • Include 0.1-0.3% Triton X-100 in blocking solution

  • Add 0.1% Tween-20 to antibody diluent

• Antigen retrieval modifications:

  • Compare heat-induced epitope retrieval methods (citrate vs. EDTA buffers)

  • Optimize retrieval duration and temperature

• Signal amplification alternatives:

  • Test polymer-based detection systems

  • Consider tyramide signal amplification for low abundance targets

• Background reduction strategies:

  • Include 0.1-0.3% hydrogen peroxide to block endogenous peroxidases

  • Add avidin/biotin blocking for biotin-based detection systems

  • Include 5-10% serum from the secondary antibody host species

How can I use FAT4 antibodies to study its role in the Wnt/β-catenin pathway in cancer models?

To investigate FAT4's interaction with Wnt/β-catenin:

• Co-immunoprecipitation approaches:

  • Use FAT4 antibodies to pull down protein complexes and probe for β-catenin

  • Reverse co-IP with β-catenin antibodies to confirm interaction

  • Include controls for specificity (IgG control, FAT4-depleted samples)

• Subcellular localization studies:

  • Dual immunofluorescence for FAT4 and β-catenin

  • Nuclear/cytoplasmic fractionation followed by western blotting

  • Live cell imaging with fluorescently tagged proteins

• Functional assays:

  • TOP/FOP luciferase reporter assays after FAT4 overexpression or knockdown

  • β-catenin phosphorylation state analysis using phospho-specific antibodies

  • Expression analysis of Wnt target genes

• In vivo cancer models:

  • FAT4 overexpression in cervical cancer xenografts to study tumor regression

  • Analysis of cytotoxic T lymphocyte infiltration and activation

  • Correlation with PD-L1 expression and glycosylation status

Research has shown that FAT4 binds to β-catenin and antagonizes its nuclear localization, promoting phosphorylation and degradation of β-catenin by the degradation complexes (AXIN1, APC, GSK3β, CK1) .

What methodological approaches can be used to study FAT4-mediated regulation of PD-L1 glycosylation?

To investigate FAT4's impact on PD-L1 glycosylation:

• Glycosylation analysis techniques:

  • PNGase F or Endo H treatment followed by western blot to detect glycosylation shifts

  • Lectin blotting to characterize glycan structures

  • Mass spectrometry for detailed glycan profiling

• Protein interaction studies:

  • Co-IP of FAT4 with STT3A (the glycosyltransferase implicated in PD-L1 glycosylation)

  • Proximity ligation assay to visualize interactions in situ

  • FRET/BRET analysis for direct protein interactions

• Subcellular trafficking analysis:

  • Track PD-L1 localization using ER, Golgi, and membrane markers

  • Pulse-chase experiments to follow glycoprotein maturation

  • Live cell imaging of fluorescently tagged PD-L1

• Functional immune assays:

  • T cell killing assays using FAT4-overexpressing cancer cells

  • Flow cytometry to quantify surface vs. intracellular PD-L1

  • Analysis of T cell activation markers in co-culture systems

Research has demonstrated that FAT4 overexpression decreases PD-L1 mRNA expression at the transcriptional level and causes aberrant glycosylation via STT3A, leading to endoplasmic reticulum accumulation and polyubiquitination-dependent degradation of PD-L1 .

How should I quantify and interpret FAT4 expression levels across different experimental conditions?

For accurate quantification and interpretation:

• Normalization strategies:

  • For western blotting: normalize to stable housekeeping proteins (β-actin, GAPDH)

  • For immunofluorescence: use total cell number or area for normalization

  • For flow cytometry: report median fluorescence intensity (MFI)

• Statistical approaches:

  • Use appropriate statistical tests based on data distribution

  • Include biological replicates (n≥3) for meaningful statistical analysis

  • Consider power analysis to determine required sample sizes

• Visual data presentation:

  • Show representative images alongside quantification

  • Include scale bars and magnification information

  • Present blots with molecular weight markers visible

• Comparative analysis:

  • Include appropriate positive and negative controls

  • Consider tissue/cell type-specific expression patterns

  • Account for FAT4 isoform variations in different contexts

• Biological significance assessment:

  • Correlate expression changes with functional outcomes

  • Compare with other markers in the same pathway (β-catenin, PD-L1)

  • Validate findings with alternative techniques

What specific challenges might arise when studying FAT4 in different cellular compartments?

Compartment-specific challenges include:

• Membrane localization:

  • FAT4 is a single-pass type I membrane protein requiring specific extraction methods

  • Extraction efficiency varies with different detergents

  • Membrane proteins often require specialized separation techniques

• Nuclear detection:

  • FAT4 interactions with β-catenin may occur in different compartments

  • Nuclear extraction protocols may affect protein-protein interactions

  • Discriminating specific nuclear signal from background

• Cytoskeletal associations:

  • FAT4's role in planar cell polarity suggests cytoskeletal interactions

  • Fixation methods may alter cytoskeletal preservation

  • Triple staining with cytoskeletal markers may be technically challenging

• Primary cilia localization:

  • FAT4 localizes to primary cilia in kidney cells

  • Cilia are small structures requiring high-resolution imaging

  • Specialized cilia preparation and fixation may be necessary

• Methods to address these challenges:

  • Differential extraction protocols for specific compartments

  • Super-resolution microscopy for small structures

  • Correlative light and electron microscopy for ultrastructural localization

  • Live cell imaging to track dynamic localization changes

What are the most effective methods to study FAT4 overexpression effects in cancer models?

For studying FAT4 overexpression:

• Expression system selection:

  • Lentiviral systems for stable integration (as used in published research)

  • CRISPR activation systems using dCas9-VP64 for endogenous upregulation

  • Inducible expression systems to control timing of FAT4 expression

• Experimental design considerations:

  • Multiple cancer cell lines to ensure effect consistency

  • Time-course studies to capture dynamic effects

  • Paired in vitro and in vivo approaches

• Functional readouts:

  • Proliferation and clonogenic assays

  • Invasion and migration assays

  • Tumor xenograft studies in both immunodeficient and immunocompetent models

• Molecular analyses:

  • Pathway analysis with key markers (β-catenin, PD-L1, STT3A)

  • Transcriptomic profiling to identify global changes

  • Protein interaction studies using antibody-based techniques

Research protocols have demonstrated successful FAT4 overexpression using lentiviral systems, with puromycin and G418 selection to establish stable cell lines, followed by validation via western blotting and qPCR .

How can I design experiments to address contradictory findings about FAT4 function in different cellular contexts?

To address contradictory findings:

• Systematic comparison approach:

  • Use identical reagents across different cell types

  • Standardize protocols for direct comparison

  • Include positive and negative controls for each system

• Context-dependent variables to consider:

  • Cell type-specific expression of FAT4 binding partners

  • Isoform expression differences between tissues

  • Activation status of related signaling pathways

• Mechanistic dissection:

  • Domain-specific mutants to identify context-dependent functions

  • Partial knockdown vs. complete knockout phenotypes

  • Rescue experiments with different FAT4 variants

• Multi-omics integration:

  • Combine transcriptomic, proteomic, and interactomic approaches

  • Identify cell type-specific protein interaction networks

  • Map post-translational modifications across contexts

• Collaborative research design:

  • Develop standard operating procedures across labs

  • Share validated reagents and cell lines

  • Implement blinded analysis to reduce bias